Switzerland
ND BioSciences is a Switzerland-based biotechnology startup established in 2019 with the mission of revolutionizing the treatment and diagnosis of neurodegenerative diseases (NDs). The company's innovative approach focuses on developing next-generation therapeutics and diagnostics tailored to address both the early and late stages of NDs. This is achieved through the creation of combination therapies aimed at preventing the onset of pathological protein aggregation and neutralizing the activities of existing protein aggregates.
What sets ND BioSciences apart are its integrated proprietary platforms, which serve as the backbone of its groundbreaking drug discovery and preclinical development initiatives. These platforms enable the company to reverse-engineer the complexity of protein aggregates observed in NDs under controlled conditions, model fundamental processes underlying the formation of protein pathologies and neurodegeneration in living neurons, and create novel companion diagnostic assays and imaging agents capturing the diversity and complexity of protein pathology in patients' brains.
The company's commitment to embracing complexity and addressing the multifaceted nature of NDs is encapsulated in its slogan: "Innovating through embracing complexity." The momentum of ND BioSciences was further bolstered by a recent grant investment on 18 January 2022 from the Michael J. Fox Foundation, emphasizing the industry's recognition of its potential impact in the biotechnology landscape.
